Silence Therapeutics plc: Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results

Positive SLN360 data to be presented in late breaker at the American College of Cardiology (ACC) Annual Meeting on April 3, 2022 SLN124 phase 1 study in thalassemia now fully enrolled; on-track for

Related Keywords

China ,New York ,United States ,Taiwan ,Hong Kong ,United Kingdom ,Macau ,London ,City Of ,American ,Rhonda Hellums ,Craig Tooman ,Mary Conway ,Hansoh Pharma ,Mallinckrodt Pharmaceuticals ,American Society Of Hematology Annual Meeting ,American College Of Cardiology ,Hepcidin Regulation Program ,Lpa Lowering Program ,Nasdaq ,Exchange Commission ,Astrazeneca ,Corporate Communications ,Program Updates ,American College ,Annual Meeting ,Chief Executive Officer ,Chief Financial Officer ,Hematology Annual ,Greater China ,Year End Highlights ,Securities Litigation Reform Act ,Admission Document ,Annual Report ,Silence ,Herapeutics ,Reports ,Fourth ,Quarter ,Bull ,Ear ,021 ,Results ,